0.000USD0.000Pre-market 07/24, 09:30 (ET)
9.35BMarket Cap
LossP/E TTM
Ionis Pharmaceuticals Inc
Key Figures
53.710Open
57.480High
2.16KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.00%Turnover Ratio
55.870Prev. Close
53.350Low
21.71KTurnover
LossP/E Static
19.03P/B
0.00%Div Yield TTM
-10.44%ROA
86.74052wk High
-0.00Volume Ratio
-453.90MNet Profit
165.90MShares
-2.0190EPS TTM
0.38Beta
-67.62%ROE
32.00052wk Low
7.39%Amplitude
98.79%Gross Margin
9.35BMarket Cap
-12.33Reward/Risk
2.19%Risk Rate
Currency: USD Updated: 2026-07-23 Key Insights
Ionis Pharmaceuticals Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 1 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 90.24.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ionis Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Ionis Pharmaceuticals Inc Highlights
StrengthsRisks
Ionis Pharmaceuticals Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ionis Pharmaceuticals Inc
IONS
25
CRISPR Therapeutics AG
CRSP
27
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Ionis Pharmaceuticals Inc Info
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Ticker SymbolIONS
CompanyIonis Pharmaceuticals Inc
CEOMonia (Brett P)
Websitehttps://www.ionis.com/
Shareholders
FAQs
What is the current price of Ionis Pharmaceuticals Inc (IONS)?
The current price of Ionis Pharmaceuticals Inc (IONS) is 55.88.
What is the symbol of Ionis Pharmaceuticals Inc?
The ticker symbol of Ionis Pharmaceuticals Inc is IONS.
What is the 52-week high of Ionis Pharmaceuticals Inc?
The 52-week high of Ionis Pharmaceuticals Inc is 86.74.
What is the 52-week low of Ionis Pharmaceuticals Inc?
The 52-week low of Ionis Pharmaceuticals Inc is 32.00.
What is the market capitalization of Ionis Pharmaceuticals Inc?
The market capitalization of Ionis Pharmaceuticals Inc is 9.27B.
Is Ionis Pharmaceuticals Inc (IONS) currently rated as Buy, Hold, or Sell?
According to analysts, Ionis Pharmaceuticals Inc (IONS) has an overall rating of Buy, with a price target of 90.24.
What is the Earnings Per Share (EPS TTM) of Ionis Pharmaceuticals Inc (IONS)?
The Earnings Per Share (EPS TTM) of Ionis Pharmaceuticals Inc (IONS) is -2.38.
